Table II.
Cumulative Incidence of Angioedema by Follow‐Up Month
| Cumulative Incidence, n (%) Follow‐Up, mo | |||||
|---|---|---|---|---|---|
| Baseline characteristics | Sample Size* | 12 | 24 | 36 | 48 |
| Number (% of ALLHAT cohort) Step 1 (assigned) treatment group | 42,418 | 35 (0.08) | 39 (0.09) | 43 (0.10) | 49 (0.12) |
| Chlorthalidone | 15,255 | 2 (0.01) | 2 (0.01) | 3 (0.02) | 6 (0.04) |
| Amlodipine | 9048 | 3 (0.03) | 3 (0.03) | 3 (0.03) | 3 (0.03) |
| Lisinopril | 9054 | 26 (0.29) | 29 (0.32) | 32 (0.35) | 35 (0.39) |
| Doxazosin | 9061 | 4 (0.04) | 5 (0.06) | 5 (0.06) | 5 (0.06) |
| Age group, y | |||||
| 55–65 | 20,127 | 18 (0.09) | 21 (0.10) | 22 (0.11) | 26 (0.13) |
| 66–75 | 16,200 | 12 (0.07) | 12 (0.07) | 14 (0.09) | 16 (0.10) |
| >75 | 6091 | 5 (0.08) | 6 (0.10) | 7 (0.11) | 7 (0.11) |
| Gender | |||||
| Male | 22,577 | 19 (0.08) | 22 (0.10) | 26 (0.12) | 29 (0.13) |
| Female | 19,841 | 16 (0.08) | 17 (0.09) | 17 (0.09) | 20 (0.10) |
| Race | |||||
| Black | 15,084 | 23 (0.15) | 25 (0.17) | 26 (0.17) | 27 (0.18) |
| Nonblack | 27,333 | 12 (0.04) | 14 (0.05) | 17 (0.06) | 22 (0.08) |
| On BP treatment ≥2 mo | 36,836 | 32 (0.09) | 36 (0.10) | 38 (0.10) | 42 (0.11) |
| On BP treatment ≤2 mo | 1428 | 1 (0.07) | 1 (0.07) | 3 (0.21) | 3 (0.21) |
| Untreated at baseline | 4153 | 2 (0.05) | 2 (0.05) | 2 (0.05) | 4 (0.10) |
| Current smoker | 9269 | 14 (0.15) | 16 (0.17) | 16 (0.17) | 18 (0.19) |
| History of diabetes | 15,283 | 5 (0.03) | 5 (0.03) | 5 (0.03) | 6 (0.04) |
| History of coronary heart disease | 10,766 | 8 (0.07) | 10 (0.09) | 11 (0.10) | 15 (0.14) |
| Aspirin use | 15,223 | 10 (0.07) | 12 (0.08) | 15 (0.10) | 17 (0.11) |
| Participants randomized late did not have follow‐up beyond 48 months. ALLHAT indicates Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial. *Sample size drops off with time. | |||||